Severe COVID-19 is associated with hyperactivation of the alternative complement pathway.

Authors:
Boussier J; Yatim N; Marchal A; Hadjadj J; Charbit B and 12 more

Journal:
J Allergy Clin Immunol

Publication Year: 2021

DOI:
10.1016/j.jaci.2021.11.004

PMCID:
PMC8595971

PMID:
34800432

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Allergy Clin Immunol

Abbreviation: J Allergy Clin Immunol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Autoimmunity and immunodeficiency associated with monoallelic LIG4 mutations via haploinsufficiency.
Jauch AJ; Bignucolo O; Seki S and 34 more (2023) - Transparency Score: 3/6
Development of mouse models with restricted HLA-B∗57:01 presentation for the study of flucloxacilli…
Ananthula S; Krishnaveni Sivakumar K; Cardone M and 6 more (2023) - Transparency Score: 3/6
Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inf…
LeSuer WE; Kienzl M; Ochkur SI and 7 more (2023) - Transparency Score: 4/6
Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and m…
Bucciol G; COVID Human Genetic Effort; Meyts I. (2023) - Transparency Score: 3/6
Phospholipid remodeling and its derivatives are associated with COVID-19 severity.
Wei J; Liu X; Xiao W and 13 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest."

Evidence found in paper:

"Supported by the Fonds IMMUNOV, for Innovation in Immunopathology; the Institut national de la santé et de la recherche médicale (Inserm); a government grant managed by the Agence national de la recherche as part of the Investment for the Future program (ANR-10-IAHU-01); and by grants from the Agence national de la recherche (ANR-flash COVID-19 “AIROCovid” and “CoVarImm”). We also acknowledge funding from the Institut Pasteur for COVID-19 Research and an Institut Imagine MD-PhD Fellowship Program award supported by the Fondation Bettencourt Schueller (to J.H.)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025